As a major transcription factor of cellular antioxidant response, accumulated evidence has suggested that activation of Nrf2 may have potential therapeutic in multiple cardiovascular diseases, such as heart failure, diabetes, diabetic nephropathy, and DCM39–42. This evidence concerns the gene NFE2L2 and diabetes mellitus.